Various immune-activating cytokines and chemokines (i.e. CXCL11, CCL2/5/19, FLTL3, IFN-α/β/γ, IL2/7/12/15/18/23/24, TNF-α, etc.)are being investigated on preclinical tumor models (neuroblastoma, breast tumor, lymphoma, lung cancer, glioma, melanoma, etc.)and in clinical trials (35). This evidence concerns the gene IL2 and neoplasm.